ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...

Shares of ResMed Inc. RMD shed 2.23% to $237.18 Thursday, on what proved to be an all-around mixed trading session for the ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

RMD's stellar second-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its ...

ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst was upbeat.

ResMed’s competitive edge is strong, but its current valuation seems inflated. Read why RMD stock might be ripe for ...

The US-based Australian sleep apnoea device giant has exceeded expectations with strong second quarter numbers.

ResMed Inc (RMD) reports a 10% revenue increase and significant margin expansion, driven by robust device sales and strategic ...

William Blair lowered their Q3 2025 EPS estimates for ResMed in a research report issued on Monday, February 3rd. William Blair analyst M. Andrew now anticipates that the medical equipment provider ...

ResMed’s (ASX:RMD) half-year FY25 results reflect a company that is not only thriving in its core business but is also ...

Operational efficiency was highlighted by a 9% increase in selling, general, and administrative expenses that still managed to decrease as a percentage of revenue. The quarter saw ResMed continue ...